Abbott’s beat comes with a cancer-deal asterisk

Beat first, questions second

Abbott’s Q1 update landed with the kind of message investors love for about five seconds: the company beat expectations. But like finding out your friend “just wants to talk,” there’s a catch — the Exact Sciences deal is now part of the conversation too.

The deal is doing the side-eye work

Even when the quarter looks solid, big M&A has a way of barging into the room and rearranging the furniture. The Exact Sciences acquisition is the sort of move that can make long-term sense and still annoy people in the short term, especially if it squeezes margins or changes the outlook math.

Why you should care

For shareholders, the real question isn’t just whether Abbott beat this quarter. It’s whether the company can keep the growth story intact while swallowing a major cancer-testing asset without blowing up profitability.

Big picture

This is classic Wall Street: a good earnings print can still feel like a mixed bag if a giant acquisition is sitting on your lap. If Abbott can prove the deal is strategic rather than expensive, the market may eventually get over the sticker shock.